Latest news
Racura Oncology cleared to escalate RC220 to 100 mg/m2 in phase 1 trial in EGFR-mutant non-small cell lung cancer
The Safety Review Committee (SRC) for a clinical trial has cleared Racura Oncology’s lead oncology drug, RC220 to escalate...
Immorta Bio pioneers AI-designed senolytic immunotherapy targeting diseases of aging
Immorta Bio, a biotechnology company pioneering therapies targeting fundamental mechanisms of aging, has completed preclinical studies for SenoMune-0257, an...
Pfizer’s Litfulo significantly improved facial and total body repigmentation in patients with nonsegmental vitiligo
Pfizer has presented results from two phase 3 trials evaluating the efficacy and safety of Litfulo (ritlecitinib) as a...
Novo Nordisk’s Wegovy (semaglutide) reduced liver fat to normal levels in nine out of 10 adults with obesity and excess liver fat – EASD2026
Novo Nordisk has presented post hoc analysis of data from a trial sub-population with 55 participants, showing that Wegovy...
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new phase 3 trial, alongside significant improvements in glycaemic control in people with obesity...
Boehringer Ingelheim has announced positive results from a phase 3 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide...
Biogen’s Litifilimab demonstrates rapid and durable efficacy in new 52-week phase 2 data from ongoing phase 2/3 study, reinforcing its potential as a first-in-class...
Biogen has announced 52-week results from the phase 2 part of the ongoing phase 2/3 study of litifilimab in...
Johnson & Johnson announces new Icotyde (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through two-years, affirming its use as a powerful first...
Johnson & Johnson has announced new two-year data from a phase 3 study demonstrating the positive impact of Icotyde...
Anixa Biosciences announces first case of stable disease for three months in ovarian cancer CAR-T clinical trial
Anixa Biosciences, a biotechnology company focused on the treatment and prevention of cancer, has announced that a patient in...
Vial doses first patient with asthma in phase 1b study of Vial’s IL-13 x TSLP, a bispecific antibody designed for twice-yearly dosing
Vial, a clinical-stage biotechnology company, has dosed the first patient in its phase 1b clinical study of Vial's IL-13...
Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease, as phase 2 trial begins
H Lundbeck has announced results from an open-label phase 1b trial evaluating Lu AF28996, a novel, investigational, oral prodrug...
AbbVie and Genmab announce epcoritamab in combination with R-CHOP demonstrates significant improvement in progression-free survival versus R-CHOP in patients with newly diagnosed diffuse large...
AbbVie has announced positive topline results from the phase 3 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody...
New partnership expands UK trial access for potential world-first vaccine against killer infection
Jane Lyons is the first person dosed in this study
Thousands of older people across the UK stand to benefit from...
Allegro’s Hydrocelin significantly improves knee osteoarthritis pain and function in clinical trial
Allegro NV, a biomedical company developing a transformative nanotechnology treatment for osteoarthritis, has announced statistically significant improvements in pain...
ENA Respiratory begins part B dosing in INNA-051 phase 2a community study designed to protect against symptomatic viral respiratory infections
ENA Respiratory, a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral infections in at-risk...
Just – Evotec Biologics advances US Department of War antibodies against orthopoxvirus into phase 1 clinical studies
Evotec SE has announced the initiation of a phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal...
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
Novartis has announced positive topline results from its phase 3 trials of remibrutinib in relapsing multiple sclerosis.
Remibrutinib, a highly...
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
GSK presented positive phase 2 data for its mRNA seasonal influenza (flu) vaccine candidate at the Options XIII Conference...
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
Eli Lilly and Company (NYSE: LLY) has announced 52-week results from Together-PsO and Together-PsA, two novel open-label phase 3b clinical trials...
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
BridgeBio Pharma has presented new analyses from the phase 3 study of Attruby (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM),...
Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Amgen and AstraZeneca have announced positive top-line results from the phase 3 trial of Tezspire (tezepelumab-ekko) in patients living with...
Late-breaking data for Abbott’s Tactiflex Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases
Abbott, the global healthcare leader, has announced new late-breaking 12-month data from the FlexPulse Global IDE study that show...
Teva announces positive topline results from phase 2a study in celiac disease for its anti-IL-15 antibody, further validating its pipeline-in-a-product potential
Teva Pharmaceutical has announced positive topline results from an ongoing phase 2a study of TEV ‘408, an investigational anti-interleukin-15...
Raziel Therapeutics and Fosun Pharma announce positive phase 3 results for RZL-012 in submental fat reduction, clearing the path to a China NDA filing
Raziel Therapeutics has announced positive results from its phase 3 registration trial in China evaluating RZL-012 for the reduction...
AbbVie announces positive topline results from the phase 3 trial showing Etentamig significantly improved response rate and progression-free survival in patients with relapsed/refractory multiple...
AbbVie has announced positive topline results from a phase 3 study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager,...
African Bundibugyo ebolavirus vaccine candidate advanced to clinical trials
Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Popular